The LYCRA Company Previews Bio-Derived LYCRA® EcoMade Fiber at ISPO
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel industry, announced today that it is promoting its bio-derived LYCRA® EcoMade fiber at ISPO, December 3 to 5. The company is showcasing samples featuring the renewable elastane in Hall A3, Stand 101, and offering visitors a fully immersive VR experience to learn about the product. It will also be featured in the Sustainability Hub (Hall A2) and is the subject of a presentation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241202374744/en/
UpFit Capsule Collection from LIVE! includes leggings, top, and jumpsuit that are made with bio-derived LYCRA® EcoMade fiber, providing exceptional comfort, fit, and flexibility with the added benefit of being a more sustainable fiber. (Photo: Business Wire)
Bio-derived LYCRA® EcoMade fiber won two ISPO Textrends Awards for Fall/Winter 2026/27. In the fibers and insulation category, this renewable elastane won a “Top 5 Award,” and a garment made with the same fabric was recognized as a “Selection” in the pants & tights category. The Brazilian activewear and swimwear brand LIVE! produced the fabric and leggings using preview samples of this highly anticipated fiber.
Launching in 2025, bio-derived LYCRA® EcoMade fiber will be the world’s first large-scale commercially available renewable elastane. The award-winning product previewed at ISPO contains 70 percent renewable content and is certified under the USDA Bio-Preferred Program. The fiber delivers equivalent performance to the original LYCRA® fiber, and no re-engineering of fabrics, processes, or garment patterns is required.
“We believe bio-derived LYCRA® EcoMade fiber represents an exciting future where we can make real, transformative change in the industry without sacrificing performance,” said Steve Stewart, The LYCRA Company’s chief brand and innovation officer. “We are thrilled to receive this recognition from ISPO and applaud our customer LIVE! for creating the award-winning fabric and garment.”
The LIVE! brand is renowned for its high-quality, sustainable apparel, and its UpFit Capsule Collection includes the ISPO award-winning leggings, Bermuda-length leggings, a top, and a jumpsuit. These garments made with bio-derived LYCRA® EcoMade fiber provide exceptional comfort, fit, and flexibility with the added benefit of being a more sustainable fiber.
“At LIVE!, we believe the future of fashion must balance innovation with environmental responsibility,” said Joice Sens, founder and creative director at LIVE!. “This collection embodies the spirit of LIVE! FUTURE, our sustainable innovation lab, and highlights the importance of partnerships like this one with the LYCRA® brand, enabling us to develop products that combine cutting-edge technology with reduced impact."
Steve Stewart is presenting “All In: The Power of Partnership” on ISPO’s Green Stage on December 4 at 16:00 CET. His presentation details how collaboration has been critical to commercializing bio-derived LYCRA® EcoMade fiber and bringing it to market.
Visit The LYCRA Company’s ISPO Event Page for show information and to discover the range of sustainable solutions fueling its exhibit: COOLMAX® and THERMOLITE® EcoMade fibers made from textile waste, and LYCRA® FiT400™ fiber designed for circularity, are made with the planet in mind. To learn more about bio-derived LYCRA® EcoMade fiber, visit this webpage for product information.
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
LYCRA®, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202374744/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release
The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom